Comparing MiniLap and Standard Laparoscopy for Preventive Surgery in BRCA-Mutated Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of MiniLap compared to standard laparoscopy in patients with BRCA mutations undergoing prophylactic bilateral salpingo-oophorectomy. The primary focus is on evaluating differences in operative duration, blood loss, and postoperative complications between the two surgical techniques. Additionally, the study aims to assess postoperative pain levels and patient satisfaction regarding aesthetic outcomes. Patients will be randomly assigned to either surgical approach, and data will be collected through the hospital's electronic management system.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients undergoing prophylactic bilateral adnexectomy via laparoscopic surgery.
* Patients with a germline mutation in the BRCA1/2 gene.

Exclusion Criteria:

* Patients who underwent additional surgery during the adnexectomy procedure.
* Patients in whom an intraoperative frozen section is required.

Where it's running

• Department of Maternal and Child Health, Obstetrics and Gynecology Clinic, University Hospital of Udine
  Udine, Udine, Italy Recruiting

Study contacts

• Study coordinator: Stefano Restaino
• Email: stefano.restaino@asufc.sanita.fvg.it
• Phone: +390432559653

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Measuring circulating mutation burden (cfMB) in women with BRCA mutations and their sisters

  This trial will test whether a blood test that measures circulating mutation burden (cfMB) differs between cancer-free women who carry a BRCA1/2 mutation and their non-carrier sisters.

  Recruiting Centre Francois Baclesse · Caen, France · NCT06792721

• Using Olaparib for Advanced Prostate Cancer

  This study is testing how well the drug olaparib works for men with advanced prostate cancer who have specific genetic changes, to see if it helps them live longer and feel better.

  Recruiting at 2 sites Santa Chiara Hospital · Naples and 1 other locations · NCT06783127

• SYN818 for advanced or metastatic solid tumors

  This Phase 1 study will test oral SYN818 in adults with advanced or metastatic solid tumors, including breast, ovarian, and prostate cancers, whose standard treatments have been exhausted.

  Recruiting at 2 sites Phase 1 Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · Zhengzhou, Henan and 1 other locations · NCT06666270

• Polygenic Risk Scores and Early Detection for Ovarian Cancer in BRCA1/2 Carriers

  This study tests how women with BRCA1/2 mutations feel about using polygenic risk scores and early-detection tests to guide cancer screening and risk-reducing decisions.

  Recruiting Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT06436248

• Testing a new drug ETX-19477 for advanced solid tumors

  This study is testing a new drug called ETX-19477 to see if it can help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting at 14 sites Phase 1/2 858 Therapeutics, Inc. · Phoenix, Arizona and 13 other locations · NCT06395519

• Predicting BRCA gene status from healthy ovarian ultrasound images

  This study is testing if ultrasound images of healthy ovaries can help predict whether women carry the BRCA gene that increases their risk for breast cancer.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome · NCT05769517

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.